Sublingual Immunotherapy (SLIT) | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

8,889 results for “Sublingual Immunotherapy (SLIT)”

Trials

View all 4816 →

Efficacy and Safety of Sublingual Immunotherapy (SLIT)

120 participants · First posted Nov 13, 2009

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

209 participants · First posted Jul 1, 2022

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

628 participants · First posted Aug 23, 2006

Drugs

View all 278 →

Latex allergy sublingual immunotherapy (ALK-Albello)

House dust mite allergy immunotherapy sublingual

Allergy immunotherapy sublingual - Stallergenes Greer plc

Organizations

View all 30 →

PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

United States

Janssen Alzheimer Immunotherapy Research & Development LLC

United States

PETER MACCALLUM CANCER INSTITUTE

Australia

News

View all 3765 →

Sublingual Immunotherapy Faces Hurdles in Gaining Full FDA Approval

ALK's Peanut Allergy Tablet Shows Positive Results, Advances to Phase II

Stallergenes Greer to Present Paediatric Phase III YOBI Data and Real-World EfficAPSI Findings at EAACI 2026

Page 1 of 889